Diamedica Therapeutics Inc - DMAC STOCK NEWS

DiaMedica Therapeutics (Nasdaq: DMAC) announced it will release its full-year 2024 financial results after market close on March 17th, 2025, followed by a conference call on March 18th at 7:00 AM Central Time. The company will provide a business update during the call.

DiaMedica is a clinical-stage biopharmaceutical company developing treatments for severe ischemic diseases. Their lead candidate DM199 is the first pharmaceutically active recombinant form of the KLK1 protein, targeting acute ischemic stroke and preeclampsia. The protein has established therapeutic applications in Asia for treating various vascular diseases.

DiaMedica Therapeutics (Nasdaq: DMAC) has appointed Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. O'Connor brings significant biopharmaceutical industry experience, most notably as CEO of Ambrx Biopharma, where he led the company from a $40 million valuation to a $2 billion acquisition by Johnson & Johnson in just 14 months.

DiaMedica is developing treatments for acute ischemic stroke (AIS) and preeclampsia (PE). AIS accounts for 87% of all strokes and is the leading cause of combined mortality and morbidity worldwide. PE affects 50,000 severe cases annually in the United States. O'Connor's expertise spans capital markets, licensing, business development, corporate strategy, clinical development, and regulatory compliance.

O'Connor is a former U.S. Marines Captain, holds a BA from Boston University and a JD from Penn State Dickinson Law, and has served on multiple public company boards and as Vice Chairman of BioNJ.

DiaMedica Therapeutics (Nasdaq: DMAC) announced a peer-reviewed publication in the journal Stroke detailing DM199's mechanism of action for treating acute ischemic stroke (AIS). The article, scheduled for print in February 2025, explains how DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1, works as a bradykinin-producing enzyme to enhance collateral circulation and stimulate angiogenesis.

The research shows that in acute stroke animal studies, bradykinin B2 receptor expression increased 36-fold on brain endothelial cells in ischemic regions. DM199 generates bradykinin that induces local vasodilation and improves brain perfusion through three synergistic signaling pathways. The treatment's preferential effect on ischemic tissue helps avoid systemic adverse effects like hypotension when properly dosed.

The prior Phase 2 ReMEDy1 trial showed favorable clinical outcomes in AIS patients ineligible for mechanical thrombectomy. The mechanism is currently being studied in the ongoing Phase 2/3 ReMEDy2 Trial.

DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025, at 11:20am Eastern Time.

The company specializes in developing novel treatments for severe ischemic diseases, with their lead candidate DM199 being the first pharmaceutically active recombinant form of the KLK1 protein. This therapeutic approach has established presence in Asia for treating acute ischemic stroke, preeclampsia, and other vascular diseases.

Investors interested in meeting with DiaMedica's management during the conference can arrange meetings through their Oppenheimer representative.

DiaMedica Therapeutics (Nasdaq: DMAC) announces the formation of a Scientific Advisory Board (SAB) to support the development of DM199, its proprietary recombinant serine protease, for treating preeclampsia. The SAB comprises renowned experts in preeclampsia and maternal-fetal health: Professor Vincenzo Berghella, Professor Cathy Cluver, Professor Bob Silver, Professor Stephen Tong, and Professor Susan Walker. These distinguished members will collaborate with DiaMedica's leadership to accelerate the development of treatment options for this potentially fatal condition.

DiaMedica Therapeutics (DMAC) provided Q3 2024 updates on its clinical programs. The company implemented changes to its ReMEDy2 Acute Ischemic Stroke Phase 2/3 trial, expanding the trial population to include thrombolytic non-responders and increasing interim analysis sample size to 200 subjects. Top-line interim results are now expected in Q4 2025. The company's Preeclampsia Phase 2 trial received regulatory approval and dosed its first patient. Financial highlights include cash position of $50.2M as of September 30, 2024, R&D expenses increased to $5.0M in Q3, and G&A expenses remained stable at $1.9M. Cash runway extends into Q3 2026.

DiaMedica Therapeutics (Nasdaq: DMAC) has initiated dosing in its investigator-sponsored Phase 2 trial of DM199 for treating preeclampsia. The company expects to receive top-line data for Part 1A in the first half of 2025, which will evaluate DM199's safety and ability to lower blood pressure. For early-onset preeclampsia patients, researchers will assess improvements in uterine artery dilation to determine if DM199 has disease-modifying potential. The trial represents a significant milestone in developing treatments for this serious maternal health condition.

DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, announced its participation in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, in New York City. The company's management will be available for one-on-one meetings throughout the event.

DiaMedica specializes in developing treatments for severe ischemic diseases, with their lead candidate DM199 being the first pharmaceutically active recombinant form of the KLK1 protein. This therapeutic approach is already established in Asia for treating acute ischemic stroke, preeclampsia, and other vascular diseases.

DiaMedica Therapeutics (Nasdaq: DMAC) announced it will release its third quarter 2024 financial results after market close on November 13th, followed by a conference call on November 14th at 7:00 AM CT. The company, focused on developing treatments for severe ischemic diseases, will provide a business update during the call. Their lead candidate DM199 is the first pharmaceutically active recombinant form of the KLK1 protein, targeting acute ischemic stroke and preeclampsia treatment.